Ind-Swift Laboratories Limited (BOM:532305)

Market Cap	34.01B +328.6%
Revenue (ttm)	6.74B +18.9%
Net Income	573.25M -75.1%
EPS	6.47 -79.4%
Shares Out	n/a
PE Ratio	59.33
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,656
Open	404.10
Previous Close	400.00
Day's Range	388.55 - 404.15
52-Week Range	87.00 - 424.55
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 1,388
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532305

Financial Performance

In fiscal year 2026, Ind-Swift Laboratories's revenue was 6.49 billion, an increase of 13.04% compared to the previous year's 5.74 billion. Earnings were 431.25 million, a decrease of -82.78%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 7, 2026

Data Sources Report a data error